We found that HRH1 and CHRM3 were expressed at higher levels in GBM (grade IV) in comparison to lower-grade gliomas (grade II and III), while CHRM1 displayed the opposite trend (Figure S4A). This evidence concerns the gene CHRM1 and central nervous system cancer.